Emerging monoclonal antibody therapies for multiple sclerosis
1Multiple Sclerosis Center at UCSF, San Francisco, California 94117, USA. bcree@itsa.ucsf.edu
The Neurologist
|July 13, 2006
Summary
Monoclonal antibodies targeting immune cells show promise for treating multiple sclerosis (MS). These novel therapies offer potential advantages over traditional treatments, though further research is needed to confirm their benefits and safety.
Area of Science:
- Immunology
- Neurology
- Pharmacology
Background:
- Monoclonal antibodies are a novel therapeutic class targeting specific antigens.
- They can deplete immune cell lineages or block receptors, offering alternatives to small molecule drugs.
- Surface proteins on immune cells are attractive targets for these therapies.
Purpose of the Study:
- To review monoclonal antibodies under investigation for multiple sclerosis (MS) treatment.
- To assess their potential as disease-modifying therapies for MS.
Main Methods:
- Literature review of existing studies.
- Analysis of ongoing clinical trials for MS therapies.
Main Results:
- Alemtuzumab, daclizumab, rituximab, and natalizumab are monoclonal antibodies in development for MS.
- These agents demonstrate promise as disease-modifying therapies for multiple sclerosis.
- They target antigens on the surface of immune system cell lines.
Conclusions:
- Monoclonal antibodies targeting immune cells are promising for MS immune suppression.
- Clinical benefits and safety profiles require further establishment due to ongoing development.
- The specificity of these therapies may offer advantages over broad-spectrum immunosuppression.
More Related Videos
Related Concept Videos
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:31Hybridoma Technology
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...